The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
MicroRNAs in diabetic cardiomyopathy and clinical perspectives
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the heart, miRNAs are involved both in cardiogenesis (14, 15) and in disease including: diabetic cardiomyopathy, hypertrophy, ischemia, and electrical remodeling (16-22).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reactive oxygen species in cardiovascular disease
Sugamura, K., & Keaney (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.05.004 · Cited by 769 · cited 1×
“…have indicated that oxidative stress and mitochondrial dysfunction were critically involved in the etiology of diabetes-induced cardiac dysfunction (Sugamura and Keaney, 2011; Styskal et al., 2012), that could subsequently induce a cascade of complex pathophysiological events characterized by…”
BackgroundCaporali, A., Meloni, M., Völlenkle, C., Bonci, D., Sala-Newby, G. B., Addis, R., Spinetti, G., Losa, S., Masson, R., Baker, A. H., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.952325 · Cited by 397
Research works printed but not linked: 32
- Aksnes, 2007, Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population, Hypertension, 50, 467, 10.1161/HYPERTENSIONAHA.106.085654 · DOI
- Asrih, 2013, Emerging role of epigenetics and miRNA in diabetic cardiomyopathy, Cardiovasc. Pathol, 22, 117, 10.1016/j.carpath.2012.07.004 · DOI
- Bartel, 2004, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell, 116, 281, 10.1016/S0092-8674(04)00045-5 · DOI
- Baseler, 2012, miR-141 as a regulator of the mitochondrial phosphate carrier (Slc25a3) in the type 1 diabetic heart, Am. J. Physiol. Cell Physiol, 303, C1244, 10.1152/ajpcell.00137.2012 · DOI
- Chavali, 2013, Predictors and prevention of diabetic cardiomyopathy, Diabetes Metab. Syndr. Obes, 6, 151, 10.2147/DMSO.S30968 · DOI
- Chavali, 2014, Differential expression of dicer, miRNAs, and inflammatory markers in diabetic Ins2+/- Akita hearts, Cell Biochem. Biophys, 68, 25, 10.1007/s12013-013-9679-4 · DOI
- Chen, 2010, Transcriptional coactivator p300 regulates glucose-induced gene expression in endothelial cells, Am. J. Physiol. Endocrinol. Metab, 298, E127, 10.1152/ajpendo.00432.2009 · DOI · Paper page
- Fabbri, 2010, miRNAs as molecular biomarkers of cancer, Expert Rev. Mol. Diagn, 10, 435, 10.1586/erm.10.27 · DOI
- Feng, 2008, Regulation of cardiomyocyte hypertrophy in diabetes at the transcriptional level, Am. J. Physiol. Endocrinol. Metab, 294, E1119, 10.1152/ajpendo.00029.2008 · DOI
- Feng, 2010, miR133a regulates cardiomyocyte hypertrophy in diabetes, Diabetes Metab. Res. Rev, 26, 40, 10.1002/dmrr.1054 · DOI · Paper page
- Fu, 2013, MicroRNA basis of physiological hypertrophy, Front. Genet, 4, 10.3389/fgene.2013.00253 · DOI
- Huynh, 2014, Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways, Pharmacol. Ther, 142, 375, 10.1016/j.pharmthera.2014.01.003 · DOI · Paper page
- Karolina, 2011, MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus, PLoS ONE, 6, e22839, 10.1371/journal.pone.0022839 · DOI · Paper page
- Katare, 2011, Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling, Circ. Res, 108, 1238, 10.1161/CIRCRESAHA.110.239111 · DOI
- Kong, 2011, Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study, Acta Diabetol, 48, 61, 10.1007/s00592-010-0226-0 · DOI · Paper page
- Lim, 2005, Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs, Nature, 433, 769, 10.1038/nature03315 · DOI · Paper page
- Lu, 2010, MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism, Cardiovasc. Res, 86, 410, 10.1093/cvr/cvq010 · DOI · Paper page
- McClelland, 2014, microRNA in the development of diabetic complications, Clin. Sci. Lond. Engl, 126, 95, 10.1042/CS20130079 · DOI
- Ruiz, 2013, MicroRNAs: the underlying mediators of pathogenetic processes in vascular complications of diabetes, Can. J. Diabetes, 37, 339, 10.1016/j.jcjd.2013.07.003 · DOI
- Shan, 2010, miR-1/miR-206 regulate Hsp60 expression contributing to glucose-mediated apoptosis in cardiomyocytes, FEBS Lett, 584, 3592, 10.1016/j.febslet.2010.07.027 · DOI · Paper page
- Shantikumar, 2012, Role of microRNAs in diabetes and its cardiovascular complications, Cardiovasc. Res, 93, 583, 10.1093/cvr/cvr300 · DOI · Paper page
- Shen, 2011, MicroRNAs involved in the mitogen-activated protein kinase cascades pathway during glucose-induced cardiomyocyte hypertrophy, Am. J. Pathol, 179, 639, 10.1016/j.ajpath.2011.04.034 · DOI
- Styskal, 2012, Oxidative stress and diabetes: what can we learn about insulin resistance from antioxidant mutant mouse models?, Free Radic. Biol. Med, 52, 46, 10.1016/j.freeradbiomed.2011.10.441 · DOI · Paper page
- Tijsen, 2012, Circulating microRNAs as diagnostic biomarkers for cardiovascular diseases, Am. J. Physiol. Heart Circ. Physiol, 303, H1085, 10.1152/ajpheart.00191.2012 · DOI · Paper page
- Tyagi, 2011, Synergy of microRNA and stem cell: a novel therapeutic approach for diabetes mellitus and cardiovascular diseases, Curr. Diabetes Rev, 7, 367, 10.2174/157339911797579179 · DOI
- Van Rooij, 2011, The art of microRNA research, Circ. Res, 108, 219, 10.1161/CIRCRESAHA.110.227496 · DOI · Paper page
- Vickers, 2014, MicroRNAs in the onset and development of cardiovascular disease, Clin. Sci. Lond. Engl, 126, 183, 10.1042/CS20130203 · DOI
- Xiao, 2012, MicroRNA-204 is required for differentiation of human-derived cardiomyocyte progenitor cells, J. Mol. Cell. Cardiol, 53, 751, 10.1016/j.yjmcc.2012.08.024 · DOI
- Xu, 2012, Circulating microRNAs: novel biomarkers for cardiovascular diseases, J. Mol. Med. Berl. Ger, 90, 865, 10.1007/s00109-011-0840-5 · DOI · Paper page
- Yildirim, 2013, Relationship between downregulation of miRNAs and increase of oxidative stress in the development of diabetic cardiac dysfunction: junctin as a target protein of miR-1, Cell Biochem. Biophys, 67, 1397, 10.1007/s12013-013-9672-y · DOI
- Yu, 2008, Glucose induces apoptosis of cardiomyocytes via microRNA-1 and IGF-1, Biochem. Biophys. Res. Commun, 376, 548, 10.1016/j.bbrc.2008.09.025 · DOI · Paper page
- Zampetaki, 2010, Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes, Circ. Res, 107, 810, 10.1161/CIRCRESAHA.110.226357 · DOI · Paper page
Cited by
Molecular and Cellular Mechanisms of Cardiovascular Disorders in Diabetes
Shah, M. S., & Brownlee, M. (2016) · Circulation Research · doi:10.1161/circresaha.116.306923 · Cited by 602
Epigenetic mechanisms in diabetic complications and metabolic memory
Reddy, M. A., Zhang, E., & Natarajan, R. (2015) · Diabetologia · doi:10.1007/s00125-014-3462-y · Cited by 496
Soller, K. J., Yang, J., Veglia, G., & Bowser, M. T. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.738807 · Cited by 20
Metadata
- Authors
- Zhou, Q., Lv, D., Chen, P., Xu, T., Fu, S., Li, J., & Bei, Y.
- Venue
- Frontiers in Genetics
- Publisher
- Frontiers Media SA
- Published
- 2014-06-25
- Volume
- 5
- ISSN
- 1664-8021
- Cited by
- 29
- References
- 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.